The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor.

Trial Profile

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Stroke; Venous thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 27 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top